Abstract
A novel metallomacrocyclic silver complex [Ag(C13H13N5)]2Br21 and a bimetallic bridged gold complex [Au2(C13H13N5)Cl2] 2 derived from 2,6-bis(3-methylimidazolin-2-yliden-1-yl)pyridine dibromide L1 have been synthesized and fully characterized by UV–Vis, elemental analysis, FT-IR, NMR techniques and DFT calculations. The DNA interactions with the compounds were investigated by UV-spectrophotometric studies, viscosity measurements and DNA electrophoresis. Additionally, the lipophilicity values were determined from the water/n-octanol partition coefficient. Experimental data indicated that all the compounds interacted with DNA, through a non-covalent binding mode. L1 and 2 were found to be hydrophilic character while 1 was somewhat lipophilic. The biological activities of L1, 1 and 2 were tested against a panel of cancer cell lines (MCF-7, PC-3, A459, HeLa, HT-29 and the 4T1 murine tumor cell line). In vitro antiviral studies against HIV-1 were performed in infected MT4 leukemia cells. All the compounds exhibited a low activity against the cell lines, associated possibly with low lipophilicity values. However, complexes 1 and 2 showed remarkable viral inhibition at low concentrations. The complexes may inhibit virus infectivity through interaction with the HIV-1 envelope proteins.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
